Key points are not available for this paper at this time.
No takes yet. Share an insight, caveat, or question.
Heterogeneity of MBP-specific T cells may limit single-peptide therapies in MS; leaves open identification of dominant or shared targets.
Meinl et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: